XML 128 R114.htm IDEA: XBRL DOCUMENT v3.22.1
Supplemental Financial Information - Cash Flows (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
Cash flows from operating activities      
Net income $ 594.8 $ 890.9  
Adjustments to reconcile net income to net cash flows from operating activities:      
Depreciation and amortization 19.4 13.4  
Equity-based compensation 39.7 32.4  
Non-cash performance allocations and incentive fees (300.8) (865.4)  
Non-cash principal investment income (315.3) (176.2)  
Other non-cash amounts 5.3 8.5  
Purchases of investments (307.5) (63.8)  
Proceeds from the sale of investments 158.3 156.0  
Payments of contingent consideration (5.7) (49.9)  
Changes in deferred taxes, net 110.9 260.3  
Change in due from affiliates and other receivables (9.5) (6.8)  
Change in deposits and other (39.8) (1.4)  
Change in accounts payable, accrued expenses and other liabilities (14.3) (69.1)  
Change in accrued compensation and benefits (580.1) (328.0)  
Change in due to affiliates (0.2) (0.4)  
Change in lease right-of-use assets and lease liabilities (2.5) 2.6  
Change in deferred revenue 254.5 255.8  
Net cash provided by (used in) operating activities (371.7) 69.5  
Cash flows from investing activities      
Purchases of fixed assets, net (12.3) (9.7)  
Purchase of CBAM intangibles and investments, net (618.4) 0.0  
Net cash used in investing activities (630.7) (9.7)  
Cash flows from financing activities      
Payments on CLO borrowings (8.9) (66.6)  
Proceeds from CLO borrowings, net of financing costs 40.8 43.4  
Dividends to common stockholders (89.5) (88.7)  
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)  
Contributions from non-controlling interest holders 146.8 3.7  
Distributions to non-controlling interest holders (147.1) (15.3)  
Common shares issued for performance allocations 31.3 0.0  
Common shares repurchased (80.4) (10.0)  
Change in due to/from affiliates financing activities 33.1 71.1  
Net cash used in financing activities (164.5) (151.2)  
Effect of foreign exchange rate changes (17.4) (11.2)  
Decrease in cash, cash equivalents and restricted cash (1,184.3) (102.6)  
Cash, cash equivalents and restricted cash, beginning of period 2,475.1 989.6  
Cash, cash equivalents and restricted cash, end of period 1,290.8 887.0  
Supplemental non-cash disclosures      
Issuance of common shares related to the acquisition of CBAM intangibles and investments 194.5 0.0  
Reconciliation of cash, cash equivalents and restricted cash, end of period:      
Cash and cash equivalents 1,290.2 880.4 $ 2,469.5
Restricted cash 0.6 6.6 5.6
Total cash, cash equivalents and restricted cash, end of period 1,290.8 887.0 2,475.1
Cash and cash equivalents held at Consolidated Funds 168.9 174.6 147.8
Consolidated Operating Entities      
Cash flows from operating activities      
Net income 569.7 891.0  
Adjustments to reconcile net income to net cash flows from operating activities:      
Depreciation and amortization 19.4 13.4  
Equity-based compensation 39.7 32.4  
Non-cash performance allocations and incentive fees (300.8) (865.4)  
Non-cash principal investment income (295.4) (186.5)  
Other non-cash amounts 5.3 8.5  
Purchases of investments (294.1) (71.6)  
Proceeds from the sale of investments 169.5 164.3  
Payments of contingent consideration (5.7) (49.9)  
Changes in deferred taxes, net 110.9 260.3  
Change in due from affiliates and other receivables (8.8) (5.4)  
Change in deposits and other (39.8) (1.4)  
Change in accounts payable, accrued expenses and other liabilities (14.3) (69.1)  
Change in accrued compensation and benefits (580.1) (328.0)  
Change in due to affiliates (0.2) (0.4)  
Change in lease right-of-use assets and lease liabilities (2.5) 2.6  
Change in deferred revenue 254.5 255.8  
Net cash provided by (used in) operating activities (372.7) 50.6  
Cash flows from investing activities      
Purchases of fixed assets, net (12.3) (9.7)  
Net cash used in investing activities (630.7) (9.7)  
Cash flows from financing activities      
Payments on CLO borrowings (8.9) (66.6)  
Proceeds from CLO borrowings, net of financing costs 40.8 43.4  
Dividends to common stockholders (89.5) (88.7)  
Payment of deferred consideration for Carlyle Holdings units (68.8) (68.8)  
Contributions from non-controlling interest holders 5.8 3.7  
Distributions to non-controlling interest holders (27.1) (15.3)  
Common shares repurchased (80.4) (10.0)  
Change in due to/from affiliates financing activities 33.1 71.1  
Net cash used in financing activities (163.7) (131.2)  
Effect of foreign exchange rate changes (17.2) (12.3)  
Decrease in cash, cash equivalents and restricted cash (1,184.3) (102.6)  
Cash, cash equivalents and restricted cash, beginning of period 2,475.1 989.6  
Cash, cash equivalents and restricted cash, end of period 1,290.8 887.0  
Reconciliation of cash, cash equivalents and restricted cash, end of period:      
Cash and cash equivalents 1,290.2 880.4  
Restricted cash 0.6 6.6  
Total cash, cash equivalents and restricted cash, end of period 1,290.8 887.0 $ 2,475.1
Cash and cash equivalents held at Consolidated Funds $ 168.9 $ 174.6